Candesan candesartan cilexetil tablets

Candesan is a prescription medication containing candesartan cilexetil, used primarily to treat high blood pressure (hypertension) and heart failure. It belongs to the class of drugs known as angiotensin II receptor blockers (ARBs).

The Candesan brand is part of the Sandoz portfolio. Sandoz was originally the generic pharmaceuticals division of the Swiss multinational Novartis, but it became a fully independent, publicly traded company in October 2023. This product is widely distributed in the Australian market, where it is listed on the Australian Register of Therapeutic Goods (ARTG).

Manufacturing for Sandoz products like Candesan often occurs across a global network of facilities, with major production hubs located in Europe and Australia to serve oceanic markets. Following its spin-off from Novartis, Sandoz is now the ultimate owner of the brand, maintaining its global headquarters in Basel, Switzerland.